Boehringer Ingelheim struck a licensing deal with Immunitas Therapeutics for a preclinical antibody program aimed at chronic inflammatory and autoimmune diseases. Financial terms call for an undisclosed upfront payment plus potential milestones and royalties totaling up to $478 million. The antibody is designed to selectively eliminate pathogenic cells at inflammation sites rather than broadly suppressing individual inflammatory signals. Boehringer will take responsibility for global development, manufacturing, and commercialization. Immunitas CEO Amanda Wagner said the partnership is intended to accelerate the program into clinical development with Boehringer’s global immunology and drug-development capabilities. For the broader pipeline, the deal highlights continuing pharma interest in precision immunology approaches that attempt to improve duration and depth of disease control for patients who fail existing therapies.